UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 56

Sortiert nach

One-Year Glycemic Control With a Sulfonylurea Plus Pioglitazone Versus a Sulfonylurea Plus Metformin in Patients With Type 2 Diabetes

Diabetes care, 2004-01, Vol.27 (1), p.141-147

2004

Volltextzugriff (PDF)

One-tear glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes

Diabetes care, 2004, Vol.27 (1), p.141-147

2004

Volltextzugriff (PDF)

Individualisierung der antihypertensiven Therapie bei Patient:innen mit Diabetes mellitus. Leitlinie der Österreichischen Diabetes Gesellschaft (Update 2023)

Wiener Klinische Wochenschrift, 2023, Vol.135 (Suppl 1), p.147-156

2023

Volltextzugriff (PDF)

Individualisierung der antihypertensiven Therapie bei Patienten mit Diabetes mellitus. Leitlinie der Österreichischen Diabetes Gesellschaft (Update 2019)

Wiener Klinische Wochenschrift, 2019-05, Vol.131 (Suppl 1), p.124-135

2019

Volltextzugriff (PDF)

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

The Lancet (British edition), 2013-01, Vol.381 (9861), p.117-124

2013

Volltextzugriff (PDF)

Adult-Onset Autoimmune Diabetes in Europe Is Prevalent With a Broad Clinical Phenotype: Action LADA 7

Diabetes care, 2013-04, Vol.36 (4), p.908-913

2013

Volltextzugriff (PDF)

Individualising antihypertensive therapy in patients with diabetes. A guideline by the Austrian Diabetes Association (update 2023)

Wiener Klinische Wochenschrift, 2023-01, Vol.135 (Suppl 1), p.147-156

2023

Volltextzugriff (PDF)

Strict glycaemic control in diabetic patients with CKD or ESRD: beneficial or deadly?

Nephrology, dialysis, transplantation, 2010-07, Vol.25 (7), p.2044-2047

2010

Volltextzugriff (PDF)

Individualisierung der antihypertensiven Therapie bei Patient:innen mit Diabetes mellitus. Leitlinie der Österreichischen Diabetes Gesellschaft (Update 2023)

Wiener Klinische Wochenschrift, 2023-01, Vol.135 (Suppl 1), p.147-156

2023

Volltextzugriff (PDF)

Antihyperglykämische Therapie bei Diabetes mellitus Typ 2 (Update 2023)

Wiener Klinische Wochenschrift, 2023, Vol.135 (Suppl 1), p.32-44

2023

Volltextzugriff (PDF)

Individualising antihypertensive therapy in patients with diabetes. A guideline by the Austrian Diabetes Association (Update 2019)

Wiener Klinische Wochenschrift, 2019-05, Vol.131 (Suppl 1), p.124-135

2019

Volltextzugriff (PDF)

Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial : Clinical implications and limitations

Journal of the American Society of Nephrology, 2005-10, Vol.16 (10), p.3027-3037

2005

Volltextzugriff (PDF)

Circulating angiopoietic cells and diabetic retinopathy in type 2 diabetes mellitus, with or without macrovascular disease

Investigative ophthalmology & visual science, 2011-06, Vol.52 (7), p.4655-4662

2011

Volltextzugriff (PDF)

Inverse Relationship Between Organ-Specific Autoantibodies and Systemic Immune Mediators in Type 1 Diabetes and Type 2 Diabetes: Action LADA 11

Diabetes care, 2016-11, Vol.39 (11), p.1932-1939

2016

Volltextzugriff (PDF)

Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials

The Lancet (British edition), 2008-10, Vol.372 (9647), p.1394-1402

2008

Volltextzugriff (PDF)

Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial

The Lancet (British edition), 2008-10, Vol.372 (9647), p.1385-1393

2008

Volltextzugriff (PDF)

YKL-40 in type 2 diabetic patients with different levels of albuminuria

European journal of clinical investigation, 2011-06, Vol.41 (6), p.589-596

2011

Volltextzugriff (PDF)

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)

European heart journal, 2007-01, Vol.28 (1), p.88-136

2007

Volltextzugriff (PDF)

Antihyperglycemic treatment guidelines for diabetes mellitus type 2 (Update 2023)

Wiener Klinische Wochenschrift, 2023-01, Vol.135, p.32-44

2023

Volltextzugriff (PDF)

Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial

Diabetic medicine, 2013-11, Vol.30 (11), p.1298-1304

2013

Volltextzugriff (PDF)

Sulodexide for Kidney Protection in Type 2 Diabetes Patients With Microalbuminuria: A Randomized Controlled Trial

American journal of kidney diseases, 2011-11, Vol.58 (5), p.729-736

2011

Volltextzugriff (PDF)

Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D)

Therapeutics and clinical risk management, 2017-01, Vol.13, p.1569-1576

2017

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(48)

Publikationsform

Artikel
(56)

Sprache

Englisch
(40)
Deutsch
(16)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Humans
(38)
Life Sciences & Biomedicine
(38)
Science & Technology
(38)
Middle Aged
(23)
Adult
(20)
Male
(18)
Female
(17)
Biological And Medical Sciences
(15)
Diabetes
(14)
Medical Sciences
(14)
Diabetes Mellitus, Type 2 - Drug Therapy
(13)
Aged
(12)
Endocrinology & Metabolism
(12)
Endocrinopathies
(11)
Diabetes. Impaired Glucose Tolerance
(10)
Endocrine Pancreas. Apud Cells
(10)
General & Internal Medicine
(10)
Medicine, General & Internal
(10)
Endocrinology
(9)
Etiopathogenesis. Screening. Investigations. Target Tissue Resistance
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

One-Year Glycemic Control With a Sulfonylurea Plus Pioglitazone Versus a Sulfonylurea Plus Metformin in Patients With Type 2 Diabetes

One-tear glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes

Individualisierung der antihypertensiven Therapie bei Patient:innen mit Diabetes mellitus. Leitlinie der Österreichischen Diabetes Gesellschaft (Update 2023)

Individualisierung der antihypertensiven Therapie bei Patienten mit Diabetes mellitus. Leitlinie der Österreichischen Diabetes Gesellschaft (Update 2019)

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

Adult-Onset Autoimmune Diabetes in Europe Is Prevalent With a Broad Clinical Phenotype: Action LADA 7

Individualising antihypertensive therapy in patients with diabetes. A guideline by the Austrian Diabetes Association (update 2023)

Strict glycaemic control in diabetic patients with CKD or ESRD: beneficial or deadly?

Individualisierung der antihypertensiven Therapie bei Patient:innen mit Diabetes mellitus. Leitlinie der Österreichischen Diabetes Gesellschaft (Update 2023)

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

Antihyperglykämische Therapie bei Diabetes mellitus Typ 2 (Update 2023)

Individualising antihypertensive therapy in patients with diabetes. A guideline by the Austrian Diabetes Association (Update 2019)

Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial : Clinical implications and limitations

Circulating angiopoietic cells and diabetic retinopathy in type 2 diabetes mellitus, with or without macrovascular disease

Antihyperglykämische Therapie bei Diabetes mellitus Typ 2 (Update 2019)

Inverse Relationship Between Organ-Specific Autoantibodies and Systemic Immune Mediators in Type 1 Diabetes and Type 2 Diabetes: Action LADA 11

Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials

Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial

YKL-40 in type 2 diabetic patients with different levels of albuminuria

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)

Antihyperglycemic treatment guidelines for diabetes mellitus type 2 (Update 2023)

Insulintherapie bei Typ 2 Diabetes mellitus (Update 2019)

Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial

Sulodexide for Kidney Protection in Type 2 Diabetes Patients With Microalbuminuria: A Randomized Controlled Trial

Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D)

Suchergebnisse filtern